Health Condition 1: L501- Idiopathic urticaria
Conditions
Interventions
Intervention1: Injection 1 ml Histaglobin along with daily dose of second generation antihistamine tab cetrizine
: Injection 1 ml Histaglobin which is combination of human normal immunoglobulin 12 mg
Sponsors
Dr Mali Kalpana Ramanna
Eligibility
Inclusion criteria
Inclusion criteria: Presence of symptoms for more than 6 weeks Not on treatment for Chronic Spontaneous Urticaria with any antihistamines or drugs for minimum 2 weeks
Exclusion criteria
Exclusion criteria: Patients with infective foci Patients with dental implants Patients on steroid therapy/immunosuppressants, chronic autoimmune conditions. Pregnant women,lactating women Physical urticaria types such as cold-induced, pressure, heat-contact, solar, dermographic, vibratory, aquagenic, cholinergic, and drug-induced urticaria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the urticaria activity scoreTimepoint: Change in the urticaria activity score from baseline to 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Number in each group achieving complete or partial symptom control Corelation of ASST positivity with UAS Duration in days patients remains symptom free or minimum symptoms Improvement in the quality of life Number, incidence, nature of adverse event Change in the serum IgE & absolute Eosinophilic Count Timepoint: Adverse events will be recorded weekly & other parameters will be at baseline & at 6 weeks | — |
Countries
India
Contacts
Public ContactDr Madhavi Eerike
All India Institute of Medical Sciences Bibinagar Hyderabad
Outcome results
None listed